Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cystatin-SN (CST1) is a type 2 cystatin, a member of the cystatin superfamily of cysteine proteinase inhibitors, encoded by the CST1 gene on human chromosome 20. CST1 is secreted in various bodily fluids including saliva, tears, urine, and seminal fluid, and primarily inhibits cysteine proteases such as papain and dipeptidyl peptidase I, contributing to the regulation of extracellular proteolysis. CST1 forms tight complexes with its target enzymes to block inappropriate tissue degradation and may play a protective role in antimicrobial defense. Elevated CST1 expression is associated with increased proliferation and metastasis in colorectal and gastric cancers, likely due to its regulatory interaction with other protease inhibitors such as CST3 (cystatin C), which shifts the balance of protease activity in favor of tumor invasion.
Protease inhibition: drugs could modulate CST1's interaction with cysteine proteases or its regulatory effect on protease activity (e.g., cathepsins). Interference with CST1/CST3/CTSB interactions to inhibit tumor cell invasion.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cystatin-SN (CST1).